Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 668

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 668
---
 holder would be entitled
to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of New Semnur Common Stock to be issued to the warrant holder.

New Semnur Private Placement Warrants

The Private
Placement Warrants will be identical to the Public Warrants underlying the Public Units except that such Private Placement Warrants, including the New Semnur Common Stock issuable upon exercise of the Private Placement Warrants, may not be
transferred, assigned or sold until 30 days after the closing of the Business Combination, subject to certain exceptions.

The foregoing summary of the
terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this proxy
statement/prospectus forms a part.

Transfer Agent and Registrar

Upon the consummation of the Business Combination, the transfer agent and registrar for New Semnur Common Stock will be VStock. The transfer agent’s
address is 18 Lafayette Place, Woodmere, New York 11598.

Listing

Application has been made for the shares of New Semnur Common Stock and New Semnur Warrants to be approved for listing on Nasdaq under the symbols
“SMNR” and “SMNRW” respectively. As of the date hereof, such listing has not been approved and there can be no assurance that New Semnur’s Nasdaq listing application will be approved prior to the Business Combination
and New Semnur’s approval to list its securities on Nasdaq is not a closing condition in the Merger Agreement.

421

SECURITIES ELIGIBLE FOR FUTURE SALE Pursuant to Rule 144 under the Securities Act (“Rule 144”), a person who has beneficially owned restricted common stock or warrants of New Semnur for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been an affiliate of New Semnur at the time of, or at any time during the three months preceding, a sale and (ii) New Semnur is subject to the Exchange Act periodic requirements for at least three months before the sale and have filed all required reports under Section 13 or 15(d) of the Exchange Act during the twelve months (or such shorter period as New Semnur was required to file reports) preceding the sale. Persons who have beneficially owned